Solid Q1 growth for Glenmark as it awaits India sitagliptin verdict
This article was originally published in Scrip
Executive Summary
Glenmark Pharmaceuticals has reported a 19% increase in revenues to INR12.37bn ($221.85m) for the first quarter ended June, backed by robust growth across its business segments in key geographies.